Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

BIRMINGHAM, Ala., Oct. 20 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) and partner Shionogi & Co., Ltd. (Shionogi) today announced that positive Phase 2 data on peramivir, a potent neuraminidase inhibitor for the treatment of influenza, has been accepted as a late-breaker poster at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/ Infectious Diseases Society of America (IDSA) 46th annual meeting taking place from October 25 to October 28 in Washington, D.C. The study was conducted by BioCryst's development partner, Shionogi.

The poster titled, "A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients" (Poster Session # 302: Respiratory Viruses I: Influenza and RSV) will be presented on Tuesday, October 28 from 12:15 p.m. - 1:15 p.m. Eastern Time in Hall C by Dr. Shigeru Kohno, Dean, Nagasaki University Graduate School of Medicine and Professor, Infection Immunology Department, Nagasaki University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

About Peramivir

Peramivir is an antiviral agent that inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against viral strains that are resistant to currently available treatments and has been safely administered to healthy subjects at high dose levels. Peramivir is currently being studied in hospitalized and outpatient flu, utilizing either an intramuscular or intravenous formulation. BioCryst is currently conducting two Phase 2 studies with peramivir, a study in subjects with acute, uncomplicated influenza, and a study in subjects with acute se
'/>"/>

SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... 28, 2014 It’s a hard truth: Nearly ... to further their post-secondary education are failing to obtain a ... this year. And according to an analysis by The ... veteran students’ uninformed choice of college majors, which leads to ... the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... July 28, 2014 The global market ... by 2020, according to a new study by Grand ... rising demand for effective vaccines and drugs in an ... medical needs is expected to drive market demand over ... enhance agricultural productivity via the use of genetically engineered ...
(Date:7/28/2014)... 2014  InterMune, Inc. (NASDAQ: ITMN ) ... 2014 financial results at the close of the U.S. ... and webcast will be hosted by InterMune at 4:30 ... investors and others may participate in the conference call ... ID#21728775. A replay of the webcast and teleconference will be ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4InterMune to Release Second Quarter Financial Results on August 6 2
... , , , , , ... in eukaryotic cell cultures , requires double-stranded molecules known ... licensed supplier of siRNA, offering a custom , ... directed against common target genes, and a Cancer , ...
... For transfection of eukaryotic cells with RNA and siRNA , , , , , , ... Kit Contents , Storage and Stability ... Technical Assistance , Product Use Limitations ... Safety Information , ...
... QIAshredder spin columns are designed for simple and rapid homogenization , of cell and tissue lysates. ... , , Format: , ... , , Sample source: , ... plant cell or tissue lysates, white blood cell lysates, , ...
Cached Biology Technology:RNAi Gene Silencing System 2RNAi Gene Silencing System 3TransMessenger Transfection Reagent Handbook 2TransMessenger Transfection Reagent Handbook 3TransMessenger Transfection Reagent Handbook 4TransMessenger Transfection Reagent Handbook 5TransMessenger Transfection Reagent Handbook 6TransMessenger Transfection Reagent Handbook 7TransMessenger Transfection Reagent Handbook 8TransMessenger Transfection Reagent Handbook 9TransMessenger Transfection Reagent Handbook 10TransMessenger Transfection Reagent Handbook 11TransMessenger Transfection Reagent Handbook 12TransMessenger Transfection Reagent Handbook 13TransMessenger Transfection Reagent Handbook 14TransMessenger Transfection Reagent Handbook 15TransMessenger Transfection Reagent Handbook 16TransMessenger Transfection Reagent Handbook 17TransMessenger Transfection Reagent Handbook 18TransMessenger Transfection Reagent Handbook 19TransMessenger Transfection Reagent Handbook 20TransMessenger Transfection Reagent Handbook 21TransMessenger Transfection Reagent Handbook 22TransMessenger Transfection Reagent Handbook 23TransMessenger Transfection Reagent Handbook 24TransMessenger Transfection Reagent Handbook 25QIAshredder Homogenizer 2
(Date:7/28/2014)... Roald Amundsen became the first man to reach the ... years later, an international team of scientists led by ... proven that air pollution from industrial activities arrived long ... from widely spaced locations around the Antarctic continent, including ... and precise reconstruction to date of lead pollution over ...
(Date:7/27/2014)... in vitro study has revealed that nicotine and cotinine, ... caused by a certain carcinogen in smoke. , The ... of tobacco leaves and ultimately ends up in the ... lung and liver, where it is activated by a ... in mice has revealed that nicotine can partially interfere ...
(Date:7/27/2014)... that wiped them out if it had taken place ... A fresh study using up-to-date fossil records and improved ... narrative of the prehistoric creatures, demise, some 66 million ... million years before a 10km-wide asteroid struck what is ... extensive volcanic activity, changing sea levels and varying temperatures. ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2
... to make proteins, key building blocks of all organisms, ... instructions for assembling them. An Iowa State ... marking where these instructions are located in a cell,s ... Journal of Biological Chemistry , Michael Shogren-Knaak, assistant professor ...
... Service scientists have completed a study on a beetle that ... attacked 67 percent of the oak trees in an area ... in the current issue of The Pan-Pacific Entomologist ... so rare it does not even have an accepted common ...
... of Eve to the venomous murder of the mighty Thor, ... of mischief and misery. The worldwide prominence of ... to the serpentbut why, when so few of us have ... Davis, anthropology professor Lynne A. Isbell suggests, lies in the ...
Cached Biology News:New Southern California beetle killing oaks 2
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
... small volume applications, including pediatric, neonatal, geriatric, general adult, veterinary and experimental animals. Automatic Calibration with ... ... ... ...
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
Biology Products: